查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
治療性抗體的全球市場：依型態、疾病領域、起源、給藥途徑- 預測至 2028 年
市場調查報告書
商品編碼
1396468

治療性抗體的全球市場：依型態、疾病領域、起源、給藥途徑- 預測至 2028 年

Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 307 Pages | 訂單完成後即時交付

價格
簡介目錄

報告摘要

調查範圍
調查年份 2023-2028
基準年 2022年
預測期 2023-2028
單元 金額（美元）
部分 型態、疾病領域、給藥途徑、來源、最終用戶
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

抗體治療市場規模預計將從 2023 年的 2,473 億美元成長到 2028 年的 4,790 億美元，預測期內年複合成長率為 14.1%。

推動抗體治療市場成長的關鍵因素包括過去五年產品核可數量的增加以及抗體工程的進步。此外，新興國家的成長機會也是該市場的機會領域。

從來源來看，人源化部門佔有率最大，2022年，人源化部門也將錄得最高成長率。對包括抗體療法在內的癌症治療的需求不斷增加，癌症盛行率不斷增加，以及針對癌症、自體免疫和發炎疾病的人源化抗體的高效能，已成為推動該部門成長的主要因素。

從給藥途徑來看，2022年靜脈注射部門將佔最大佔有率。該部門的成長歸因於給藥方便、功效高、市場佔有率大以及研發線產品專注於靜脈注射途徑。

從地區來看，北美所佔佔有率最大。北美地區的巨大佔有率主要是由於醫療環境中技術先進的基礎設施的存在，提供了抗體療法並且易於獲得先進的療法。此外，該地區擁有完善的醫療保健系統，進一步推動了市場成長。主要營運商在同一市場的存在也是一個重要因素。

同時，就成長率而言，歐洲地區預計在預測期內將呈現最高的年複合成長率。這是由於推進抗體療法的舉措增加、慢性病患病率上升以及主要參與者在該地區企業發展所致。

本報告調查了全球抗體治療市場，並提供了市場概況、市場成長和市場機會的各種影響因素分析、技術和專利趨勢、管道分析、法律制度以及市場規模趨勢。我們編制預測、詳細分析按不同細分領域及地區分類、競爭形勢、主要企業概況等

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
  • 波特五力分析
  • 技術分析
  • 價值鏈分析
  • 生態系分析
  • 專利分析
  • 管道分析
  • 支援鏈分析
  • 監管狀況
  • 價格分析
  • 影響客戶業務的趨勢/干擾
  • 重大會議及活動
  • 主要利害關係人和採購標準

第6章 抗體治療藥物市場：依型態

  • 單株抗體
  • 多克隆抗體
  • 抗體片段
  • 雙特異性抗體
  • 其他

第7章 抗體治療藥物市場：依疾病領域

  • 自體免疫疾病與發炎疾病
  • 瘤
  • 血
  • 感染疾病
  • 骨學
  • 免疫
  • 神經
  • 其他

第8章抗體治療藥物市場：依來源分類

  • 人類
  • 人性化
  • 嵌合體
  • 其他

第9章 抗體治療藥物市場：給藥給藥途徑

  • 靜脈注射
  • 皮下的
  • 其他

第10章抗體治療市場：依最終用戶分類

  • 醫院
  • 長期照護設施
  • 其他

第11章抗體治療市場：按地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東
  • 非洲

第12章競爭形勢

  • 主要策略
  • 市場佔有率分析
  • 市場收益分析
  • 企業評價矩陣
  • 新興企業/小型企業評估矩陣
  • 競爭格局及趨勢

第13章 公司簡介

  • 主要企業
    • F. HOFFMANN-LA ROCHE LTD.
    • ABBVIE INC.
    • JOHNSON & JOHNSON
    • MERCK KGAA
    • BRISTOL-MYERS SQUIBB
    • ASTRAZENECA
    • SANOFI
    • REGENERON PHARMACEUTICALS INC.
    • NOVARTIS AG
    • AMGEN INC.
    • BIOGEN
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • PFIZER INC.
    • ELI LILLY AND COMPANY
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • GLAXOSMITHKLINE PLC
    • UCB SA
  • 其他公司
    • EMERGENT BIOSOLUTIONS INC.
    • Y-MABS THERAPEUTICS, INC.
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • ULTRAGENYX PHARMACEUTICAL INC.
    • H. LUNDBECK A/S
    • CELLTRION INC.
    • MACROGENICS, INC.
    • MORPHOSYS AG

第14章附錄

簡介目錄
Product Code: PH 8876

Report Description

Scope of the Report
Years Considered for the Study2023-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
Segmentsformat, disease area, route of administration, source, end-user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

The antibody therapeutics market is expected to reach USD 479.0 billion by 2028 from USD 247.3 billion in 2023, at a CAGR of 14.1% during the forecast period. The key factors driving the growth of the antibody therapeutics market include the increasing number of product approvals in the last five years and growing advancements in antibody engineering, among others. Moreover, growth avenues in emerging economies are an opportunity area for this market.

The antibody therapeutics market has been segmented based on format, disease area, route of administration, source, end user and region.

"By source, the human source segment accounted for the largest share of the antibody therapeutics market."

Based on source, the antibody therapeutics market is categorized into human, humanized, chimeric and other sources. In 2022, humanized sources accounted for the highest growth rate owing to factors such as The rising demand for therapies (including antibody therapy) against cancer, increasing cancer prevalence, high effectiveness of humanized sourced antibodies against cancers and autoimmune & inflammatory diseases are the major factors driving the growth of this segment.

"By route of administration, the intravenous segment accounted for the largest share in the antibody therapeutics market."

Based on the route of administration, the antibody therapeutics market is segmented into the intravenous, subcutaneous and other routes of administration. In 2022, the intravenous route segment accounted for the largest share of the antibody therapeutics market. Growth in this market segment can be attributed to ease of administration, high effectiveness, presence of large marketed products and major focus of pipeline products on intravenous route.

"North America: the largest share of the antibody therapeutics market."

North America accounted for the largest share of the antibody therapeutics market. The large share of the North American region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering antibody therapeutics, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, the presence of some of the key players in the market is another key factor. Some examples of these players include AbbVie Inc. (US), Johnson & Johnson (US), and Bristol-Myers Squibb (US).

"Europe: The fastest-growing region in the antibody therapeutics market."

The European antibody therapeutics market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of antibody therapeutics, increasing prevalence of chronic diseases and key players such as F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Sanofi (France) operating in the region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
  • By Region: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%

Prominent Players

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie Inc. (US)
  • Johnson & Johnson (US)
  • Merck KGaA (Germany)
  • Bristol-Myers Squibb (US)
  • AstraZeneca (UK)
  • Sanofi (France)
  • Regeneron Pharmaceuticals, Inc. (US)
  • Novartis AG (Switzerland)
  • Amgen, Inc. (US)
  • Biogen Inc. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Pfizer Inc. (US)
  • Eli Lilly and Company (US)
  • Boehringer Ingelheim International GmbH (Germany)
  • GlaxoSmithKline plc (UK)
  • UCB, Inc. (Belgium)
  • Emergent BioSolutions Inc. (US)
  • Y-mAbs Therapeutics, Inc. (US)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Ultragenyx Pharmaceutical Inc. (US)
  • Lundbeck A/S (Denmark)
  • Celltrion, Inc. (South Korea)
  • MacroGenics, Inc. (US)
  • MorphoSys AG (Germany)

Research Coverage:

This report provides a detailed picture of the antibody therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as the format, disease area, route of administration, source, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the antibody therapeutics market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges. Additionally, the report is inclusive of extensive product mapping along with their revenues. The report also gives pipeline analysis of antibody therapeutic products which are expected to impact the market significantly during the forecast period.

The report provides insights on the following pointers"

  • Analysis of key drivers (growth in regulatory approvals for antibody therapeutics products), opportunities (emerging economies), restraint (stringent regulations) and challenges (manufacturing complexities) influencing the growth of the antibody therapeutics market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the antibody therapeutics market.
  • Market Development: Comprehensive information about lucrative markets- the report analyses the antibody therapeutics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the antibody therapeutics market.
  • Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others in the antibody therapeutics market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 ANTIBODY THERAPEUTICS MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • 2.3 GROWTH FORECAST
    • FIGURE 8 ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS
    • FIGURE 9 ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 LIMITATIONS
  • 2.7 RISK ANALYSIS
  • 2.8 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 11 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2023 VS. 2028 (USD BILLION)
    • FIGURE 12 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2023 VS. 2028 (USD BILLION)
    • FIGURE 13 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
    • FIGURE 14 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 15 ANTIBODY THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF ANTIBODY THERAPEUTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 ANTIBODY THERAPEUTICS MARKET OVERVIEW
    • FIGURE 17 INCREASING DEMAND FOR ANTIBODY THERAPIES IN TREATMENT OF CANCER TO DRIVE MARKET
  • 4.2 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE & COUNTRY (2022)
    • FIGURE 18 HUMAN SOURCES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
  • 4.3 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 19 INTRAVENOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED MARKET IN 2022
  • 4.4 ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Advancements in antibody engineering
      • 5.2.1.2 Rising demand for oncology therapeutics
    • TABLE 2 NUMBER OF APPROVED PRODUCTS BY US FDA/EMA (2015-2023)
      • 5.2.1.3 Advantages offered by therapeutic antibodies
      • 5.2.1.4 Increasing R&D activities for innovative therapeutics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Stringent regulatory requirements
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth potential of emerging economies
      • 5.2.3.2 Growing focus on collaborations for drug discovery & development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complexities associated with manufacturing processes
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 ANTIBODY THERAPEUTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT OF NEW ENTRANTS
    • 5.3.2 THREAT OF SUBSTITUTES
    • 5.3.3 BARGAINING POWER OF SUPPLIERS
    • 5.3.4 BARGAINING POWER OF BUYERS
    • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4 TECHNOLOGY ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 22 ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 23 ANTIBODY THERAPEUTICS MARKET: ECOSYSTEM MAP
  • 5.7 PATENT ANALYSIS
    • FIGURE 24 PATENT APPLICATIONS FOR ANTIBODY THERAPEUTIC PRODUCTS (JANUARY 2012-OCTOBER 2023)
    • TABLE 4 ANTIBODY THERAPEUTICS MARKET: INDICATIVE LIST OF PATENTS
  • 5.8 PIPELINE ANALYSIS
    • TABLE 5 ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE
  • 5.9 SUPPLY CHAIN ANALYSIS
    • FIGURE 25 ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
    • TABLE 6 SUPPLY CHAIN ECOSYSTEM
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY ANALYSIS
    • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
    • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 PRICING ANALYSIS
    • 5.11.1 AVERAGE SELLING PRICE TREND OF ANTIBODY THERAPEUTICS
    • TABLE 11 AVERAGE SELLING PRICE OF ANTIBODY THERAPEUTICS, BY KEY PLAYER
    • 5.11.2 INDICATIVE PRICING ANALYSIS
    • TABLE 12 INDICATIVE PRICING ANALYSIS OF ANTIBODY THERAPEUTIC PRODUCTS, BY ROUTE OF ADMINISTRATION
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.13 KEY CONFERENCES AND EVENTS
    • TABLE 13 ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023-2024)
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS ON BUYING PROCESS
    • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR ANTIBODY THERAPEUTICS
    • 5.14.2 BUYING CRITERIA FOR ANTIBODY THERAPEUTICS MARKET
    • FIGURE 27 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES

6 ANTIBODY THERAPEUTICS MARKET, BY FORMAT

  • 6.1 INTRODUCTION
    • TABLE 14 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
  • 6.2 MONOCLONAL ANTIBODIES
    • 6.2.1 TARGET SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET
    • TABLE 15 APPROVED MONOCLONAL ANTIBODIES
    • TABLE 16 ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 17 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 19 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 20 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 POLYCLONAL ANTIBODIES
    • 6.3.1 BROADER SPECTRUM OF TARGETS OFFERED BY POLYCLONAL ANTIBODIES TO SUPPORT MARKET GROWTH
    • TABLE 21 APPROVED POLYCLONAL ANTIBODIES
    • TABLE 22 ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 23 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 ANTIBODY FRAGMENTS
    • 6.4.1 WIDE APPLICATIONS OF ANTIBODY FRAGMENTS IN ONCOLOGY TO FUEL GROWTH
    • TABLE 27 APPROVED ANTIBODY FRAGMENTS
    • TABLE 28 ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 29 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 BISPECIFIC ANTIBODIES
    • 6.5.1 MINIMAL SIDE EFFECTS OF BISPECIFIC ANTIBODIES DUE TO TARGETED APPROACH TO FUEL ADOPTION
    • TABLE 33 APPROVED BISPECIFIC ANTIBODIES
    • TABLE 34 ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 35 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.6 OTHER NOVEL ANTIBODY THERAPIES
    • TABLE 39 APPROVED NOVEL ANTIBODY THERAPIES
    • TABLE 40 ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021-2028 (USD MILLION)

7 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA

  • 7.1 INTRODUCTION
    • TABLE 45 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • 7.2 AUTOIMMUNE & INFLAMMATORY DISEASES
    • 7.2.1 LARGE NUMBER OF MARKETED ANTIBODY THERAPEUTICS AND STRONG PIPELINE TO DRIVE MARKET
    • TABLE 46 ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 ONCOLOGY
    • 7.3.1 INITIATIVES BY MARKET PLAYERS TO DEVELOP ANTIBODY THERAPIES FOR CANCER INDICATIONS TO SUPPORT GROWTH
    • TABLE 51 ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 52 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 HEMATOLOGY
    • 7.4.1 GROWING PRODUCT ADOPTION TO SUPPORT MARKET GROWTH
    • TABLE 56 ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.5 INFECTIOUS DISEASES
    • 7.5.1 GROWING RESEARCH FOCUS ON INFECTIOUS DISEASES TO FUEL MARKET GROWTH
    • TABLE 61 ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.6 OSTEOLOGY
    • 7.6.1 GROWING FOCUS ON OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN TO SUPPORT GROWTH
    • TABLE 66 ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.7 IMMUNOLOGY
    • 7.7.1 GROWING USE OF HUMORAL IMMUNODEFICIENCY ANTIBODY THERAPEUTICS TO PROPEL MARKET GROWTH
    • TABLE 71 ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 72 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.8 NEUROLOGY
    • 7.8.1 PRESENCE OF SEVERAL MONOCLONAL ANTIBODIES FOR NEUROLOGICAL CONDITIONS TO FUEL MARKET GROWTH
    • TABLE 76 ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 77 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.9 OTHER DISEASE AREAS
    • TABLE 81 ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 82 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

8 ANTIBODY THERAPEUTICS MARKET, BY SOURCE

  • 8.1 INTRODUCTION
    • TABLE 86 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
  • 8.2 HUMAN
    • 8.2.1 REDUCED IMMUNOGENICITY OF HUMAN-SOURCED ANTIBODIES TO DRIVE GROWTH
    • TABLE 87 ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 91 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 HUMANIZED
    • 8.3.1 EFFECTIVENESS OF HUMANIZED ANTIBODY THERAPEUTICS AGAINST CANCER AND AUTOIMMUNE & INFLAMMATORY DISORDERS TO DRIVE DEMAND
    • TABLE 92 ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 93 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 CHIMERIC
    • 8.4.1 INTRODUCTION OF HYBRID DESIGNS RESULTING IN IMPROVED EFFICACY TO SUPPORT MARKET GROWTH
    • TABLE 97 ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 98 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 OTHER SOURCES
    • TABLE 102 ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 103 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 104 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)

9 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1 INTRODUCTION
    • TABLE 107 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • 9.2 INTRAVENOUS
    • 9.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
    • TABLE 108 ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 109 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 110 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 SUBCUTANEOUS
    • 9.3.1 ADVANTAGES SUCH AS FASTER ONSET OF THERAPEUTIC EFFECT TO BOOST DEMAND
    • TABLE 113 ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 114 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 115 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 116 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 OTHER ROUTES OF ADMINISTRATION
    • TABLE 118 ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 119 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 120 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)

10 ANTIBODY THERAPEUTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 123 ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2 HOSPITALS
    • 10.2.1 AVAILABILITY OF ADVANCED FACILITIES AND SUPPORT TO DRIVE MARKET
    • TABLE 124 ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 125 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 126 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 127 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 128 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 LONG-TERM CARE FACILITIES
    • 10.3.1 ADVANTAGES SUCH AS SPECIALIZED CARE AND MONITORING TO SUPPORT MARKET GROWTH
    • TABLE 129 ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 133 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 OTHER END USERS
    • TABLE 134 ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 135 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 138 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

11 ANTIBODY THERAPEUTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 139 ANTIBODY THERAPEUTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 28 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET SNAPSHOT
    • TABLE 140 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 141 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 142 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 143 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 144 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 145 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 Growing FDA approvals for novel antibody therapeutics to drive market
    • TABLE 146 US FDA ANTIBODY THERAPEUTIC PRODUCT APPROVALS
    • TABLE 147 US: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 148 US: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 149 US: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 150 US: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 151 US: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Growing cancer burden and investments in antibody research to support market growth
    • TABLE 152 CANADA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 153 CANADA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 154 CANADA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 155 CANADA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 156 CANADA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.3 NORTH AMERICA: RECESSION IMPACT
  • 11.3 EUROPE
    • FIGURE 29 EUROPE: ANTIBODY THERAPEUTICS MARKET SNAPSHOT
    • TABLE 157 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 158 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 159 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 160 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 161 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 162 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Rising incidence of cancer to drive market
    • TABLE 163 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 164 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 165 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 166 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 167 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Growing research initiatives to support market growth
    • TABLE 168 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 169 UK: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 170 UK: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 171 UK: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 172 UK: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 173 UK: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Favorable reimbursement policies to drive growth
    • TABLE 174 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 175 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 176 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 177 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 178 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Growing regulatory approvals for antibody therapeutics to support growth
    • TABLE 179 ITALY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 180 ITALY: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 181 ITALY: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 182 ITALY: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 183 ITALY: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Growing prevalence of cancer to drive market
    • TABLE 184 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 185 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 186 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 187 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 188 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 189 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 190 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 191 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 192 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 193 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.7 EUROPE: RECESSION IMPACT
  • 11.4 ASIA PACIFIC
    • TABLE 194 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 195 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 196 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 197 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 198 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 199 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Growing demand for therapeutic products to support growth
    • TABLE 200 CHINA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 201 CHINA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 202 CHINA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 203 CHINA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 204 CHINA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Growing access to quality healthcare to boost market
    • TABLE 205 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 206 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 207 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 208 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 209 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Increasing burden of chronic diseases and growing R&D initiatives to drive market
    • TABLE 210 INDIA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 211 INDIA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 212 INDIA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 213 INDIA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 214 INDIA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Favorable government initiatives to propel market
    • TABLE 215 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 216 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 217 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 218 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 219 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.5 REST OF ASIA PACIFIC
    • TABLE 220 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 221 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 222 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 223 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 224 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 11.5 LATIN AMERICA
    • TABLE 225 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 226 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 227 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 228 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 229 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 230 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.1 BRAZIL
      • 11.5.1.1 Growing demand for therapeutics against chronic diseases to drive market
    • TABLE 231 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 232 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 233 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 234 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 235 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.2 REST OF LATIN AMERICA
    • TABLE 236 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 237 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 238 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 239 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 240 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.3 LATIN AMERICA: RECESSION IMPACT
  • 11.6 MIDDLE EAST
    • 11.6.1 DEVELOPING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
    • TABLE 241 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 242 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 243 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 244 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 245 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.2 MIDDLE EAST: RECESSION IMPACT
  • 11.7 AFRICA
    • 11.7.1 INCREASING PUBLIC AND PRIVATE INVESTMENTS IN HEALTHCARE TO SUPPORT MARKET GROWTH
    • TABLE 246 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021-2028 (USD MILLION)
    • TABLE 247 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
    • TABLE 248 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 249 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 250 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.7.2 AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY STRATEGIES/RIGHT TO WIN
    • FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET
  • 12.3 MARKET SHARE ANALYSIS
    • FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
    • TABLE 251 DEGREE OF COMPETITION: ANTIBODY THERAPEUTICS MARKET
  • 12.4 MARKET REVENUE ANALYSIS
    • FIGURE 32 REVENUE ANALYSIS FOR KEY COMPANIES, 2020-2022
  • 12.5 COMPANY EVALUATION MATRIX
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 33 COMPANY EVALUATION MATRIX, 2022
    • 12.5.5 COMPANY FOOTPRINT
      • 12.5.5.1 Product footprint
    • TABLE 252 PRODUCT FOOTPRINT OF KEY PLAYERS
      • 12.5.5.2 Regional footprint
    • TABLE 253 REGIONAL FOOTPRINT OF KEY PLAYERS
  • 12.6 START-UP/SME EVALUATION MATRIX
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • FIGURE 34 START-UP/SME EVALUATION MATRIX, 2022
    • 12.6.5 COMPETITIVE BENCHMARKING
    • TABLE 254 DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 255 COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • 12.7 COMPETITIVE SCENARIOS AND TRENDS
    • 12.7.1 PRODUCT APPROVALS
    • TABLE 256 PRODUCT APPROVALS, JANUARY 2020-SEPTEMBER 2023
    • 12.7.2 DEALS
    • TABLE 257 DEALS, JANUARY 2020-SEPTEMBER 2023
    • 12.7.3 OTHER DEVELOPMENTS
    • TABLE 258 OTHER DEVELOPMENTS, JANUARY 2020-SEPTEMBER 2023

13 COMPANY PROFILES

  • (Business overview, Products/Services/Solutions offered, Recent developments & MnM View)**
  • 13.1 KEY PLAYERS
    • 13.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 259 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • TABLE 260 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES
    • TABLE 261 F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS
    • TABLE 262 F. HOFFMANN-LA ROCHE LTD.: DEALS
    • 13.1.2 ABBVIE INC.
    • TABLE 263 ABBVIE INC.: COMPANY OVERVIEW
    • FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2022)
    • TABLE 264 ABBVIE INC.: PRODUCT APPROVALS
    • TABLE 265 ABBVIE INC.: DEALS
    • 13.1.3 JOHNSON & JOHNSON
    • TABLE 266 JOHNSON & JOHNSON: COMPANY OVERVIEW
    • FIGURE 37 JOHNSON & JOHNSON: COMPANY SNAPSHOT
    • TABLE 267 JOHNSON & JOHNSON: PRODUCT APPROVALS
    • 13.1.4 MERCK KGAA
    • TABLE 268 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • TABLE 269 MERCK KGAA: PRODUCT APPROVALS
    • TABLE 270 MERCK KGAA: OTHER DEVELOPMENTS
    • 13.1.5 BRISTOL-MYERS SQUIBB
    • TABLE 271 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW
    • FIGURE 39 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2022)
    • TABLE 272 BRISTOL-MYERS SQUIBB: PRODUCT APPROVALS
    • TABLE 273 BRISTOL-MYERS SQUIBB: DEALS
    • TABLE 274 BRISTOL-MYERS SQUIBB: OTHER DEVELOPMENTS
    • 13.1.6 ASTRAZENECA
    • TABLE 275 ASTRAZENECA: COMPANY OVERVIEW
    • FIGURE 40 ASTRAZENECA: COMPANY SNAPSHOT (2022)
    • TABLE 276 ASTRAZENECA: DEALS
    • TABLE 277 ASTRAZENECA: PRODUCT APPROVALS
    • 13.1.7 SANOFI
    • TABLE 278 SANOFI: COMPANY OVERVIEW
    • FIGURE 41 SANOFI: COMPANY SNAPSHOT (2022)
    • TABLE 279 SANOFI: PRODUCT APPROVALS
    • TABLE 280 SANOFI: DEALS
    • 13.1.8 REGENERON PHARMACEUTICALS INC.
    • TABLE 281 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
    • FIGURE 42 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
    • TABLE 282 REGENERON PHARMACEUTICALS INC.: DEALS
    • TABLE 283 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS
    • 13.1.9 NOVARTIS AG
    • TABLE 284 NOVARTIS AG: COMPANY OVERVIEW
    • FIGURE 43 NOVARTIS AG: COMPANY SNAPSHOT (2022)
    • TABLE 285 NOVARTIS AG: DEALS
    • TABLE 286 NOVARTIS AG: PRODUCT APPROVALS
    • TABLE 287 NOVARTIS AG: OTHER DEVELOPMENTS
    • 13.1.10 AMGEN INC.
    • TABLE 288 AMGEN INC.: COMPANY OVERVIEW
    • FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT (2022)
    • TABLE 289 AMGEN INC.: DEALS
    • TABLE 290 AMGEN INC.: PRODUCT APPROVALS
    • TABLE 291 AMGEN INC.: OTHER DEVELOPMENTS
    • 13.1.11 BIOGEN
    • TABLE 292 BIOGEN: COMPANY OVERVIEW
    • FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT (2022)
    • TABLE 293 BIOGEN: PRODUCT APPROVALS
    • TABLE 294 BIOGEN: DEALS
    • 13.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • TABLE 295 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
    • FIGURE 46 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
    • TABLE 296 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
    • 13.1.13 PFIZER INC.
    • TABLE 297 PFIZER INC.: COMPANY OVERVIEW
    • FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT
    • TABLE 298 PFIZER INC.: PRODUCT APPROVALS
    • 13.1.14 ELI LILLY AND COMPANY
    • TABLE 299 ELI LILLY AND COMPANY: COMPANY OVERVIEW
    • FIGURE 48 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    • TABLE 300 ELI LILLY AND COMPANY: PRODUCT APPROVALS
    • TABLE 301 ELI LILLY AND COMPANY: DEALS
    • TABLE 302 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
    • 13.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • TABLE 303 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
    • FIGURE 49 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
    • TABLE 304 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS
    • TABLE 305 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS
    • TABLE 306 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS
    • 13.1.16 GLAXOSMITHKLINE PLC
    • TABLE 307 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
    • FIGURE 50 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)
    • TABLE 308 GLAXOSMITHKLINE PLC: DEALS
    • TABLE 309 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS
    • TABLE 310 GLAXOSMITHKLINE PLC: OTHER DEVELOPMENTS
    • 13.1.17 UCB S.A.
    • TABLE 311 UCB S.A.: COMPANY OVERVIEW
    • FIGURE 51 UCB S.A.: COMPANY SNAPSHOT (2022)
    • TABLE 312 UCB S.A.: DEALS
    • TABLE 313 UCB S.A.: PRODUCT APPROVALS
  • *Details on Business overview, Products/Services/Solutions offered, Recent developments & MnM View might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 EMERGENT BIOSOLUTIONS INC.
    • 13.2.2 Y-MABS THERAPEUTICS, INC.
    • 13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 13.2.4 ULTRAGENYX PHARMACEUTICAL INC.
    • 13.2.5 H. LUNDBECK A/S
    • 13.2.6 CELLTRION INC.
    • 13.2.7 MACROGENICS, INC.
    • 13.2.8 MORPHOSYS AG

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS